LEE011

CHF 60.00
In stock
SYN-1213-M0011 mgCHF 60.00
SYN-1213-M0055 mgCHF 96.00
SYN-1213-M01010 mgCHF 144.00
SYN-1213-M05050 mgCHF 419.00
SYN-1213-M100100 mgCHF 658.00
 
More Information
Product Details
Synonyms LEE-011; Ribociclib
Product Type Chemical
Properties
Formula C23H30N8O
MW 434.5
CAS 1211441-98-3
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by SynKinase.
Other Product Data Target: CDK4/CDK6 | Kinase Group: CGMC | Substrate: Serine-Threonine

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key RHXHGRAEPCAFML-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathways, with potential antineoplastic activity. Specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.
Product References
  1. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma: J. Rader, et al.; Clin. Cancer Res. 19, 6173 (2013)
  2. Molecular pathways: CDK4 inhibitors for cancer therapy: M.A. Dickson; Clin. Cancer Res. 20, 3379 (2014)
  3. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo: Y.X. Zhang, et al.; Mol. Cancer Ther. 13, 2184 (2014)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.